ProfileGDS5678 / 1427379_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 20% 20% 20% 21% 20% 19% 20% 20% 20% 20% 20% 20% 20% 22% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.4989420
GSM967853U87-EV human glioblastoma xenograft - Control 22.4809820
GSM967854U87-EV human glioblastoma xenograft - Control 32.4834520
GSM967855U87-EV human glioblastoma xenograft - Control 42.4431321
GSM967856U87-EV human glioblastoma xenograft - Control 52.4346120
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.5167819
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.5123120
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.4600720
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.45920
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.4758520
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.4637220
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.4500820
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.4768120
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.5033222